AI-driven therapeutics and novel interventions in migraine: a systematic review of emerging trends
Abstract
This systematic review aims to evaluate the effectiveness of artificial intelligence (AI) and device-based interventions in the diagnosis and treatment of migraines and other headache disorders, highlighting their potential clinical applications. A comprehensive search was conducted across PubMed, Cochrane, Web of Science, and Scopus from January 2013 to December 2023, identifying 18 relevant studies. The data were extracted using standardized forms, and a narrative synthesis was performed due to study heterogeneity. This review highlights several promising advances in migraine management and diagnosis. Several studies have highlighted key milestones where individuals experiencing migraine with aura, closure of a patent foramen ovale (PFO) using the Amplatzer device was associated with complete relief in 11% of patients. In addition, Diagnostic accuracy also saw notable improvement through the use of artificial intelligence, with correctly identified migraine cases increasing from 66.6% using traditional methods to 96.8% when AI tools were applied. Furthermore, Remote neuromodulation techniques, including Transcranial Magnetic Stimulation and electrical nerve stimulation, provided at least 50% pain relief in 66.5% of patients. Notably, the Precision Olfactory Delivery (POD) system was preferred by 67% of users over traditional nasal sprays. AI and device-based interventions showing promising results in enhancing migraine diagnosis and treatment. Clinicians should consider…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.